Citation Impact
Citing Papers
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients
2008
Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors
2005
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
2006 StandoutScience
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
2000
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial
2008
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Catalytic Asymmetric Three‐Component Synthesis of Homoallylic Amines
2013 StandoutNobel
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
2008 Standout
Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia
2002
Platinum-based chemotherapy in metastatic breast cancer: current status
2003
P-glycoprotein: from genomics to mechanism
2003
Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study.
1993
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
2003
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
2003
Cytokines and psychopathology: Lessons from interferon-α
2004
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
2009 Standout
Clinical trial participation among patients enrolled in the Glioma Outcomes Project
2002
Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemetics
2003
Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001
2002
The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly
2002
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
2005
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study
2005
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.
1993
Paclitaxel (Taxol)
1995 Standout
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
2006
Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation
2001 Standout
Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation
2000 Standout
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Acute myeloid leukaemia
2006
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
2010 Standout
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
1994
Cytokines sing the blues: inflammation and the pathogenesis of depression
2005 Standout
Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia
2004
Targeting multidrug resistance in cancer
2006 Standout
Participation in Cancer Clinical Trials
2004 Standout
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
2006
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
2009
The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
2004
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
1994
Biology and management of relapsed acute myeloid leukaemia
2005
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Malignant Gliomas in Adults
2008 Standout
Infectious and immunosuppressive complications of purine analog therapy.
1995
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
1995
Hematopoietic Stem-Cell Transplantation
2006 Standout
Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: An Illinois Cancer Council study
1989
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
2011 Standout
Considerations in the design and development of transport inhibitors as adjuncts to drug therapy
2003
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Growth factors in acute myeloid leukaemia
2001
Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome
2004
Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention
2007 Standout
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
2007 Standout
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG‐9500)
2007
Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
1994
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Reporting of Noninferiority and Equivalence Randomized Trials
2012 Standout
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission
2009
Nutritional Interventions and Outcome in Patients With Cancer or Preinvasive Lesions: Systematic Review
2006
Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia:
2004
Gene expression and hypoxia in breast cancer
2011
Behavioural and hypothalamic molecular effects of the anti-cancer agent cisplatin in the rat: A model of chemotherapy-related malaise?
2006 StandoutNobel
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
2002 Standout
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
2007 Standout
From inflammation to sickness and depression: when the immune system subjugates the brain
2007 Standout
Side Effects of Adjuvant Treatment of Breast Cancer
2001
Anemia of Chronic Disease
2005 Standout
Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission
2005
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Cancer of the Ovary
2004 Standout
The Role of ABC Transporters in Clinical Practice
2003
Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma
1999
Tumour stem cells and drug resistance
2005 Standout
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
2004
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
2002 StandoutScience
Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology
2002
The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
2001
Breast Cancer Resistance Protein in Drug Resistance of Primitive CD34+38− Cells in Acute Myeloid Leukemia
2005
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
2003 Standout
Acute Myeloid Leukemia
2015 Standout
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
2002
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Multidrug resistance protein attenuates gemtuzumab ozogamicin–induced cytotoxicity in acute myeloid leukemia cells
2003
Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621
2004
SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
2000
VX-710 (Biricodar) Increases Drug Retention and Enhances Chemosensitivity in Resistant Cells Overexpressing P-Glycoprotein, Multidrug Resistance Protein, and Breast Cancer Resistance Protein
2004
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial
2007
Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome
1999
Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
2003
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
2001
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
2001
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome
1999
Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator
2005
A multi-center, late phase II clinical trial of Genexol® (paclitaxel) and cisplatin for patients with advanced gastric cancer
2004
How I treat refractory and early relapsed acute myeloid leukemia
2015
Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial
2000
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
1997
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
2007 Standout
Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies
2004
The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin
2004
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high‐risk myelodysplastic syndromes
2003
Age and acute myeloid leukemia
2006
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study
2002
Management of Acute Myelogenous Leukemia in the Elderly
2003
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
2012
Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia
2003
Works of Harry E. Hynes being referenced
A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy
2001
Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma
1993
Analysis of Treatment Failure in Acute Nonlymphocytic Leukemia Patients over Fifty Years of Age
1992
Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer
1994
Effects of vitamin a on survival in patients with chronic myelogenous leukemia: A SWOG randomized trial
1995
Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer
1993
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia
1999
Anticipatory nausea and vomiting in the era of 5-HT 3 antiemetics
1998
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
2001
A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031)
1998
A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group study.
1995
Oral Clonidine in Postmenopausal Patients with Breast Cancer Experiencing Tamoxifen-Induced Hot Flashes: A University of Rochester Cancer Center Community Clinical Oncology Program Study
2000
A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031)
1998
Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study.
1987
Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study.
1986
Differential Effects of Paroxetine on Fatigue and Depression: A Randomized, Double-Blind Trial From the University of Rochester Cancer Center Community Clinical Oncology Program
2003
Use of 5‐HT 3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings
1999